Arctic Bioscience AS (DE:9TD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Arctic Bioscience AS has successfully completed patient recruitment for the HeROPA clinical trial, with positive progress reported including a new microalgae discovery, promising HRO350 research, and expected year-on-year revenue growth of 20-30% for 2024. Despite a slight dip in H1 2024 Nutra revenues compared to the previous year, the company has already secured sales surpassing 2023’s total, with a stable gross margin of 30.6%. The company looks forward to a potential phase III study and commercialization of HRO350, while closely monitoring liquidity and considering various financing options.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
